PPIDT00418
Drug Information
| Name | Tezepelumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB15090 |
| Type | biotech |
| Indication | Tezepelumab is indicated as an add-on maintenance treatment for patients aged 12 years and older with severe asthma.[L39504,L44712] In Europe, it is reserved for patients who are inadequately controlled despite maintenance treatment with high-dose inhaled corticosteroids plus another drug.[L44712] Tezepelumab is not indicated for the relief of acute bronchospasm or status asthmaticus.[L39504] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Subcutaneous |
210 mg
|
| Injection, solution | Subcutaneous |
210 mg/1.9mL
|
| Solution | Subcutaneous |
110 mg / mL
|
| Solution | Subcutaneous |
210.00 mg
|